Zevalin ibritumomab tiuxetan: Phase II data

In a Phase II trial in 104 elderly patients ineligible for stem cell transplantation, a single dose of ibritumomab resulted in an OR rate

Read the full 245 word article

How to gain access

Continue reading with a
two-week free trial.